Polycythemia Vera Clinical Trials

Find Polycythemia Vera Clinical Trials Near You

A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera

Status: Recruiting
Location: See all (32) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

The purpose of this study is to evaluate the efficacy and safety of sapablursen when added on to current standard of care (SOC) for Polycythemia Vera (PV) therapy. The study will be conducted in three sequential parts (Part 1a blinded treatment, Part 1b open-label treatment, \& Part 2 long-term extension). Participants may receive treatment for up to 156 weeks.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Meet revised 2022 World Health Organization (WHO) and 2022 International Consensus Classification criteria for the diagnosis of PV.

• Participants must be phlebotomy-dependent.

• Hct less than (\<) 45% at study start.

• Participants receiving Cytoreduction therapy (CRT) must be on a stable regimen at study start.

• Adequate organ function and electrolytes.

Locations
United States
California
UC Irvine Health - Chao Family Comprehensive Cancer Center
RECRUITING
Orange
Florida
Regis Clinical Research LLC.
RECRUITING
Miami
Florida Clinical Trials Group
RECRUITING
Plantation
Florida Clinical Trials Group
RECRUITING
Tamarac
Georgia
Central Georgia Cancer Care
RECRUITING
Macon
Maryland
The Center for Cancer & Blood Disorders
RECRUITING
Bethesda
Michigan
The Cancer and Hematology Centers
RECRUITING
Grand Rapids
New York
Montefiore Medical Center
RECRUITING
The Bronx
Ohio
Gabrail Cancer Center Research
RECRUITING
Canton
The James Cancer Hospital and Solove Research Institute at The Ohio State University
RECRUITING
Columbus
Pennsylvania
Fox Chase Cancer Center
RECRUITING
Philadelphia
Virginia
Hematology Oncology Associates of Fredericksburg
RECRUITING
Fredericksburg
Other Locations
Australia
Icon Cancer Centre Kurralta Park
RECRUITING
Kurralta Park
Perth Blood Institute
RECRUITING
West Perth
Brazil
Meso Clinic Servicos Medicos Ltda
RECRUITING
Blumenau
Instituto Joinvilense de Hematologia e Oncologia LTDA
RECRUITING
Santa Catarina
Hungary
Cortex Study Center
RECRUITING
Budapest
Gyor-Moson-Sopron County Petz Aladar University Teaching Hospital
RECRUITING
Győr
Japan
Japanese Red Cross Nagasaki Genbaku Hospital
RECRUITING
Nagasaki
Osaka Metropolitan University Hospital
RECRUITING
Osaka
Institute of Science Tokyo Hospital
RECRUITING
Tokyo
Tokyo Women's Medical University Hospital
RECRUITING
Tokyo
Poland
Aidport Sp. z. o. o.
RECRUITING
Skórzewo
MICS Centrum Medyczne Torun
RECRUITING
Torun
Pratia Onkologia Wroclaw
RECRUITING
Wroclaw
United Kingdom
Royal Devon University Healthcare NHS Foundation Trust
RECRUITING
Exeter
Imperial College Healthcare NHS Trust
RECRUITING
London
The New Castle upon Tyne Hospital
RECRUITING
Newcastle Upon Tyne
Royal Gwent Hospital
RECRUITING
Newport
Nottingham University Hospitals NHS Trust
RECRUITING
Nottingham
GensisCare
RECRUITING
Oxford
Genesis Care Windsor
RECRUITING
Windsor
Contact Information
Primary
Clinical Team
clinicaltrials@deciphera.com
888-724-3274
Time Frame
Start Date: 2026-05-25
Estimated Completion Date: 2031-01
Participants
Target number of participants: 250
Treatments
Experimental: Sapablursen
Sapablursen (32 Weeks) - Sapablursen (124 Weeks Open-label)
Experimental: Placebo
Placebo (32 Weeks) - Sapablursen (124 Weeks Open-label)
Related Therapeutic Areas
Sponsors
Collaborators: Deciphera Pharmaceuticals, LLC
Leads: Ono Pharmaceutical Co., Ltd.

This content was sourced from clinicaltrials.gov